[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Powell S, Dudek AZ: Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res; 2009 Oct;29(10):4189-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
  • BACKGROUND: High-dose interleukin-2 (HD IL-2) is known to produce durable responses in metastatic melanoma.
  • The purpose of this study was to evaluate the response of metastatic melanoma to treatment with HD IL-2.
  • PATIENTS AND METHODS: A retrospective analysis was performed on all adult patients with stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at the University of Minnesota.
  • HD IL-2 was given intravenously every 8 hours at 600,000 IU/kg for a maximum of 14 doses per course.
  • RESULTS: Fifteen patients with metastatic melanoma had been treated with HD IL-2.
  • There were 4 patients exhibiting some response, with 1 complete response (CR), 1 partial response (PR), 1 mixed response (MR) and 2 stable disease (SD).
  • Average time to disease progression (TTDP) was 5.67 months.
  • Two patients had complete resolution of brain lesions after HD IL-2 therapy.
  • One of these patients experienced CR and is disease free 34 months after stopping therapy.
  • The other patient experienced MR and is currently alive with disease, but without recurrence of brain lesions.
  • CONCLUSION: We propose further evaluation of HD IL-2 in patients with brain metastases because this patient population is typically considered ineligible for HD IL-2 therapy.
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Humans. L-Lactate Dehydrogenase / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846971.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


2. Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS: A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer; 2008 Oct 1;113(7):1632-40
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
  • BACKGROUND: Previous biochemotherapy regimens for metastatic melanoma have required attenuated dosages of interleukin 2 (IL-2) that may have compromised efficacy.
  • RESULTS: Thirty-eight patients with treatment-naive American Joint Committee on Cancer stage IV melanoma (8 patients with M1a disease, 6 patients with M1b disease, and 24 patients with M1c disease) were enrolled.
  • Responses were observed in patients with M1a disease and in patients with M1c disease.
  • Sixteen patients had stable disease (15 patients progressed).
  • CONCLUSIONS: The current results indicated that it is safe to administer HD IL-2 sequentially with temozolomide and that this combination has lower toxicity than previously used concurrent biochemotherapy regimens.
  • However, The ORR and the durability of responses with this combination did not exceed those of single-agent HD IL-2.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer. 2013 Feb 15;119(4):924
  • (PMID = 18720480.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA121973
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


3. Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P: Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer; 2009;9:112
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
  • BACKGROUND: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer.
  • Patients received cetuximab (400 mg/m2 initial dose and 250 mg/m2/week thereafter) and every 2 weeks irinotecan (180 mg/m2), FA (400 mg/m2) and 5-FU (either low dose [LD], 300 mg/m2 bolus plus 2,000 mg/m2 46-hour infusion, n = 7; or, high-dose [HD], 400 mg/m2 bolus plus 2,400 mg/m2; n = 45).
  • RESULTS: Only two DLTs occurred in the HD group, and HD 5-FU was selected for use in part II.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Cetuximab. Diarrhea / chemically induced. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Exanthema / chemically induced. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Metastasis. Survival Analysis. Treatment Outcome. Vomiting / chemically induced

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2005 Mar;16(3):425-9 [15677624.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):502-9 [15659495.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1311-9 [15870084.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4856-65 [15939923.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7125-34 [16192596.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9073-8 [16361615.001]
  • [Cites] Bull Cancer. 2006 Feb 1;93 Suppl 1:S45-9 [16483945.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):450-6 [16303861.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2212-21 [16904315.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4914-21 [17050875.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1166-9 [17375050.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5225-32 [18024868.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):374-9 [18202412.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1442-9 [18441330.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5335-43 [18854570.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):905-14 [11006366.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2958-70 [11595683.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22 [11597400.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):507-14 [12479268.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2454-60 [8095852.001]
  • [Cites] Hepatology. 1998 Oct;28(4):971-9 [9755233.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • (PMID = 19366444.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2678147
  •  go-up   go-down


Advertisement
4. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD: Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol; 2008 Jun;109(3):323-8
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
  • OBJECTIVE: Doxorubicin-based treatment is standard therapy for metastatic uterine leiomyosarcoma.
  • We determined activity of fixed-dose rate gemcitabine plus docetaxel as second-line treatment for metastatic uterine leiomyosarcoma.
  • An additional 50% (24/48) had stable disease (median duration 5.4 months).

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):355-7 [10955863.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):140-4 [11748990.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):48-51 [12694653.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):644-7 [14766260.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):363-8 [15140550.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):626-32 [6344983.001]
  • [Cites] Am J Clin Oncol. 1986 Feb;9(1):18-20 [3953489.001]
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1303-4 [3690545.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):32-4 [2154921.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6823-6 [2208147.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] Invest New Drugs. 1991 May;9(2):207-8 [1874603.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1962-6 [1941054.001]
  • [Cites] Am J Obstet Gynecol. 1992 Feb;166(2):556-9 [1536229.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):202-5 [1592288.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):27-30 [8626112.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):226-9 [8751554.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):145-6 [9537200.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):267-71 [9740703.001]
  • [Cites] Stat Med. 1998 Oct 30;17(20):2301-12 [9819829.001]
  • [Cites] Gynecol Oncol. 1999 Sep;74(3):346-9 [10479491.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5484-92 [16110008.001]
  • [Cites] Cancer. 2006 May 1;106(9):2051-7 [16568459.001]
  • [Cites] Tumori. 2006 Nov-Dec;92(6):542-4 [17260498.001]
  • [Cites] J Thorac Oncol. 2006 Jun;1(5):447-53 [17409898.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):508-16 [17306350.001]
  • [Cites] Invest New Drugs. 2007 Jun;25(3):279-81 [17221305.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1248-55 [11230465.001]
  • (PMID = 18394689.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] None / None / / U10 CA027469-22; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / CA27469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / U10 CA027469-22
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ NIHMS55728; NLM/ PMC2692926
  •  go-up   go-down


5. Ducreux M, Raoul JL, Marti P, Merrouche Y, Tigaud JM, Rebischung C, Boige V: High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology; 2008;74(1-2):17-24
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
  • This study aimed to determine the safety and efficacy of high-dose (HD) irinotecan combined with LV5FU2 or simplified LV5FU (LV5FUs) in first-line treatment of metastatic colorectal cancer.
  • PATIENTS AND METHODS: Patients with unresectable and measurable metastatic colorectal cancer, not pretreated for metastatic disease, were given irinotecan 260 mg/m(2) combined with LV5FU2 in the first 25 patients, then with LV5FUs (HD-FOLFIRI) in 35 patients.
  • CONCLUSION: HD-irinotecan plus LV5FU2 or HD-FOLFIRI is feasible and achieved a high response rate and postsurgery complete response rate.
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoadjuvant Therapy. Survival Analysis. Treatment Outcome


6. Yang PW, Lin HD, Wang LM: Pyogenic liver abscess associated with septic pulmonary embolism. J Chin Med Assoc; 2008 Sep;71(9):442-7
MedlinePlus Health Information. consumer health - Sepsis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Septic pulmonary embolism (SPE) is one of the metastatic foci of pyogenic liver abscess.
  • Computed tomography (CT) demonstrated metastatic nodules in both lung lobes, some of which featured cavitation, in all 9 patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiography, Thoracic. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Chin Med Assoc. 2008 Dec;71(12):603-4 [19114323.001]
  • (PMID = 18818136.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


7. Napoli N, Vattikuti S, Ma C, Rastelli A, Rayani A, Donepudi R, Asadfard M, Yarramaneni J, Ellis M, Armamento-Villareal R: High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer. Breast J; 2010 Nov-Dec;16(6):609-16
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we evaluated the vitamin D status in postmenopausal women with non-metastatic breast cancer who were about to start AI therapy.
  • This study was conducted on community dwelling postmenopausal subjects, aged 35-80 years, with early non-metastatic breast cancer (up to stage IIIA), who were about to start therapy using third generation AIs.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2767 [11352973.001]
  • [Cites] Am J Clin Nutr. 2008 Jul;88(1):133-9 [18614733.001]
  • [Cites] Am J Clin Nutr. 2003 Jan;77(1):204-10 [12499343.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4042-57 [12963702.001]
  • [Cites] N Engl J Med. 2003 Nov 6;349(19):1793-802 [14551341.001]
  • [Cites] Mayo Clin Proc. 2003 Dec;78(12):1457-9 [14661673.001]
  • [Cites] Mayo Clin Proc. 2003 Dec;78(12):1463-70 [14661675.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1081-92 [15014181.001]
  • [Cites] Anticancer Drugs. 2004 Sep;15(8):753-60 [15494636.001]
  • [Cites] J Clin Invest. 1985 Aug;76(2):470-3 [3839801.001]
  • [Cites] Arch Intern Med. 1991 Aug;151(8):1662-4 [1872673.001]
  • [Cites] J Clin Invest. 1992 Dec;90(6):2464-71 [1469098.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):1108-17 [8772584.001]
  • [Cites] Osteoporos Int. 1997;7(5):439-43 [9425501.001]
  • [Cites] Lancet. 1998 Mar 14;351(9105):805-6 [9519960.001]
  • [Cites] Am J Clin Nutr. 1998 Jun;67(6):1232-6 [9625098.001]
  • [Cites] Lancet. 2005 Jan 1-7;365(9453):60-2 [15639680.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):232-9 [15647817.001]
  • [Cites] Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73 [15863546.001]
  • [Cites] J Bone Miner Res. 2005 Aug;20(8):1327-33 [16007329.001]
  • [Cites] Mayo Clin Proc. 2006 Mar;81(3):353-73 [16529140.001]
  • [Cites] J Nutr. 2006 Apr;136(4):1126-9 [16549493.001]
  • [Cites] Am J Clin Nutr. 2006 Jul;84(1):18-28 [16825677.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):633-43 [16887480.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):2968-75 [16963261.001]
  • [Cites] Breast. 2007 Jun;16(3):223-34 [17368903.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Ann Oncol. 2007 Sep;18 Suppl 8:viii26-35 [17890211.001]
  • [Cites] Breast Cancer Res Treat. 2007;105 Suppl 1:75-89 [17912638.001]
  • [Cites] J Endocrinol Invest. 2007 Sep;30(8):653-8 [17923796.001]
  • [Cites] Nutr J. 2008;7:4 [18226257.001]
  • [Cites] Cancer Causes Control. 2008 Jun;19(5):527-35 [18219582.001]
  • [Cites] Lancet. 2002 Jun 22;359(9324):2131-9 [12090977.001]
  • (PMID = 21070438.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD01459; United States / NIAMS NIH HHS / AR / R03 AR049401; United States / NIAMS NIH HHS / AR / R21 AR053196; United States / NICHD NIH HHS / HD / K12 HD001459; United States / NIAMS NIH HHS / AR / 5R21AR053196-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; 64719-49-9 / 25-hydroxyvitamin D
  • [Other-IDs] NLM/ NIHMS250408; NLM/ PMC3689648
  •  go-up   go-down


8. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S: High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer; 2008 Jul 15;113(2):293-301
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.
  • BACKGROUND: The treatment of metastatic renal cell carcinoma (RCC) with high-dose interleukin-2 (HD IL-2) has resulted in durable tumor regression in a minority of patients.
  • METHODS: Patients with metastatic RCC (n = 259) were treated with HD IL-2 alone from January 13, 1986 through December 31, 2006 at the Surgery Branch of the National Cancer Institute.
  • All partial responders had developed disease recurrence at the time of last follow-up, but only 4 complete responders had experienced disease recurrence by that time.
  • CONCLUSIONS: HD IL-2 can induce complete tumor regression in a small number of patients, and many patients have experienced extended disease-free intervals.
  • Given its relative safety, HD IL-2 should still be considered a first-line therapy in patients with metastatic RCC who have an overall good performance status.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Indoleacetic Acids. Male. Middle Aged. National Cancer Institute (U.S.). Retrospective Studies. Survival Rate. Time Factors. United States

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5 [2679456.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1863-74 [2685181.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):161-9 [2404087.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1119-23 [1607917.001]
  • [Cites] Ann Oncol. 1992 Jun;3(6):475-80 [1498066.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 21;85(8):622-32 [8468720.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):661-70 [8478661.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1809-16 [8355047.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):497-501 [7844611.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):688-96 [7884429.001]
  • [Cites] Cancer. 1995 Aug 15;76(4):687-94 [8625167.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):307-19 [9742914.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):488-95 [16113605.001]
  • [Cites] Cancer J Sci Am. 1996 Mar-Apr;2(2):91-8 [9166506.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 18457330.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / NIH0012219327; United States / Intramural NIH HHS / / Z01 SC003811-33
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoleacetic Acids; 0 / Interleukin-2; U8EX2DRD73 / prodolic acid
  • [Other-IDs] NLM/ NIHMS411739; NLM/ PMC3486432
  •  go-up   go-down


9. Schlemmer M, Wendtner CM, Falk M, Abdel-Rahman S, Licht T, Baumert J, Straka C, Hentrich M, Salat C, Hiddemann W, Issels RD: Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology; 2006;71(1-2):32-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
  • BACKGROUND: Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy.
  • High-dose chemotherapy consisted of ifosfamide 12 g/m(2), carboplatin 1.2 g/m(2) and etoposide 1.2 g/m(2) (HD-ICE) followed by reinfusion of PBSCs.
  • All but 2 patients refusing treatment received high-dose chemotherapy with PBSC rescue leading to grade IV hematologic toxicity without severe infections in all patients.
  • By intent-to-treat analysis the probability of 5-year progression-free survival was significantly higher for patients allocated to HD-ICE compared to patients receiving second-line chemotherapy after failure of AI-G (14 vs. 3%; p = 0.003).
  • CONCLUSION: HD-ICE is feasible and promising in patients with chemosensitive MSTS.
  • A randomized phase III trial is warranted to further define the role of HD-ICE as consolidation treatment in these patients.
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Feasibility Studies. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Prospective Studies. Salvage Therapy. Survival Rate. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344669.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3
  •  go-up   go-down


10. Micha JP, Goldstein BH, Epstein HD, Rettenmaier MA, Brown JV 3rd: Ovarian cancer metastatic to the breast. Gynecol Oncol; 2006 Aug;102(2):386-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer metastatic to the breast.
  • BACKGROUND: Metastatic ovarian cancer to the breast should be considered in the differential diagnosis for gynecologic cancer patients with a breast tumor.
  • CASES: We present three ovarian cancer patients who developed metastatic ovarian cancer to the breast.
  • All patients were heavily pre-treated prior to the development of metastatic disease.
  • Currently, one patient is alive at 64 months following initial detection of her metastatic disease to the breast.
  • The second and third patients are also alive for 30 and 3 months subsequent to their diagnosis of metastatic disease.
  • CONCLUSION: Although metastatic ovarian cancer to the breast following treatment for ovarian cancer is rare and associated with a poor prognosis, oncology physicians should be prepared to contend with disease metastatic to the breast.
  • [MeSH-minor] Adult. Aged. Female. Humans


11. Dudek AZ, Yee RT, Manivel JC, Isaksson R, Yee HO: Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. Anticancer Res; 2010 Mar;30(3):987-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
  • AIM: The objectives of this study were to evaluate treatment responses to high-dose interleukin-2 (HD IL-2) in patients with metastatic renal cell carcinoma (mRCC) and assess correlation between responses and prognostic factors, such as histology, site of metastatic disease, prior treatment, prior nephrectomy, and carbonic anhydrase IX (CAIX) expression.
  • PATIENTS AND METHODS: A retrospective analysis was performed on all mRCC patients treated with HD IL-2 between 1996 and 2006 at the University of Minnesota Medical Center in Minneapolis, Minnesota, USA.
  • A cycle of HD IL-2 consisted of 600,000 U/kg given once every 8 hours for 14 doses.
  • Cycles were repeated until disease progression or intolerable toxicities developed.
  • The overall disease control rate was 42.6%.
  • The median time to disease progression in patients with a CR or PR was 12 months.
  • CONCLUSION: HD IL-2 is a reasonable option for first-line therapy for selected patients with mRCC.
  • Patients with tumors negative for CAIX may not benefit from HD IL-2 therapy.
  • Further research is necessary to define patients with a higher likelihood of disease response to this therapy.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393025.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Interleukin-2; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


12. Borget I, Aupérin A, Pignon JP, Abbas M, Bouché O, Mousseau M, Raoul JL, Bedenne L, Cassan P, Clavero-Fabri MC, Stremsdoerfer N, Nasca S, Queuniet AM, Ducreux M, Fédération Francophone de Cancérologie Digestive: Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. Oncology; 2006;71(1-2):40-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
  • BACKGROUND: The De Gramont regimen (or high-dose LV5FU2, HD-LV5FU2) is considered a standard treatment for metastatic colorectal cancer.
  • The aim of the study was to evaluate the efficacy and the costs of three regimens as compared to HD-LV5FU2: raltitrexed (R), LV5FU2 with a lower dose of folinic acid (LD-LV5FU2), and weekly infusional 5FU (WI-FU).
  • METHODS: An economic analysis was performed prospectively as part of a randomized trial comparing first-line chemotherapy regimens in 294 patients with unresectable metastatic colorectal cancer.
  • RESULTS: None of the three regimens improved EFS as compared to HD-LV5FU2.
  • The mean total cost per patient was euro 15,970 for HD-LV5FU2.
  • The cost of R (10,687 euro) was lower than that of HD-LV5FU2 (p = 0.008).
  • The cost of LD-LV5FU2 (14,888 euro) and of WI-FU (13,760 euro) was not significantly different from that of HD-LV5FU2.
  • The HD-LV5FU2 protocol remains a better treatment.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Cost of Illness. Cost-Benefit Analysis. Disease-Free Survival. Female. France. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Quinazolines / administration & dosage. Survival Rate. Thiophenes / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344670.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; FCB9EGG971 / raltitrexed; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol; 2005 Jan 1;23(1):133-41
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
  • PURPOSE: The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma.
  • PATIENTS AND METHODS: Patients were stratified for bone and liver metastases, primary tumor in place, and Eastern Cooperative Oncology Group performance status 0 or 1 and then randomly assigned to receive either IL-2 (5 MIU/m(2) subcutaneously every 8 hours for three doses on day 1, then daily 5 days/wk for 4 weeks) and IFN (5 MIU/m(2) subcutaneously three times per week for 4 weeks) every 6 weeks or HD IL-2 (600,000 U/kg/dose intravenously every 8 hours on days 1 through 5 and 15 to 19 [maximum 28 doses]) every 12 weeks.
  • The response rate was 23.2% (22 of 95 patients) for HD IL-2 versus 9.9% (nine of 91 patients) for IL-2/IFN (P = .018).
  • Ten patients receiving HD IL-2 were progression-free at 3 years versus three patients receiving IL-2 and IFN (P = .082).
  • For patients with bone or liver metastases (P = .001) or a primary tumor in place (P = .040), survival was superior with HD IL-2.
  • CONCLUSION: This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.
  • [MeSH-minor] Adult. Aged. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Metastasis. Recombinant Proteins. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):6267-8; author reply 6268-9 [16135500.001]
  • [CommentIn] J Clin Oncol. 2005 Sep 20;23(27):6797-8; author reply 6798-9 [16170190.001]
  • [ErratumIn] J Clin Oncol. 2005 Apr 20;23(12):2877
  • (PMID = 15625368.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


14. Duffour J, Gourgou S, Desseigne F, Debrigode C, Mineur L, Pinguet F, Poujol S, Chalbos P, Bressole F, Ychou M: Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Cancer Chemother Pharmacol; 2007 Aug;60(3):383-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
  • PURPOSE: Irinotecan at 180 mg/m2 combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC).
  • Efficacy and safety were determined in the intention to treat (ITT) population and in patients able to receive irinotecan at 260 mg/m2 for at least four cycles [high-dose (HD) population].
  • Among them, 44 (81.5%) formed the HD population.
  • The ITT objective response rate was 48% (90%CI: 36-60) with 25/26 of the responses in the HD population.
  • The disease control rate was 76% (90%CI: 65-85) and median overall survival was 20.4 months (90%CI: 6.4-27.1).
  • The main grade 3/4 toxicities (ITT/HD populations) were neutropenia (61%/59%), and diarrhoea (18%/11%), respectively.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Agents, Phytogenic / toxicity. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124595.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


15. Lotz JP, Curé H, Janvier M, Asselain B, Morvan F, Legros M, Audhuy B, Biron P, Guillemot M, Goubet J, Laadem A, Cailliot C, Maignan CL, Delozier T, Glaisner S, Maraninchi D, Roché H, Gisselbrecht C: High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer; 2005 Jan;41(1):71-80
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.
  • The aim of our study was to evaluate the impact on time to progression (TTP) and overall survival (OS) of high-dose chemotherapy (HD-CT) over conventional CT in metastatic breast cancer patients.
  • Between 09/92 and 12/96, 61 patients with chemosensitive metastatic breast cancer were randomised between HD-CT using the CMA regimen (Mitoxantrone, Cyclophosphamide, Melphalan) applied as consolidation (32 patients) or maintenance CT (29 patients).
  • At randomisation, 13 patients were in complete response, 47 in partial response and one had stable disease.
  • The CMA regimen could prolong the TTP of patients with chemosensitive metastatic breast cancer.
  • [MeSH-minor] Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. France. Humans. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617992.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


16. Fateh S, Schell TD, Gingrich R, Neves RI, Drabick JJ: Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. Cancer Biol Ther; 2010 Dec 1;10(11):1091-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
  • Metastatic melanoma remains a disease with a very poor prognosis.
  • High dose Interleukin-2 (HD IL-2) and temozolomide (TMZ) are both approved treatments for this malignancy but response rates remain poor.
  • HD IL-2 is the only approved therapy that has been shown to induce durable complete responses albeit in a very small percentage of patients.
  • The combination of TMZ followed by HD IL-2 as biochemotherapy has been studied previously but did not improve responses over what had been observed for HD IL-2 alone.
  • In our clinical practice, we noted surprising rapid and dramatic responses to TMZ when given as therapy at 75 mg/m2 for 21 days per one month cycles in 6/9 (67%) sequentially treated patients who had just completed a full course of HD IL-2 and either had failed to respond (11%) or frankly progressed (89%).
  • Three patients remain alive and completely disease free, two are off of all therapy to date.
  • One patient had prolonged stable disease and 2 patients progressed.
  • We hypothesize that the TMZ may be synergistic with HD IL-2 in a sequence-specific fashion by allowing the immune activation induced by the HD IL-2 to proceed without negative feedback applied by the T-reg population of cells whose major function is to inhibit an exuberant immune response.
  • The durable CRs that persist after the cessation of treatment suggest that this sequence-specific combination should be studied further, ideally in a prospective trial of repeated courses of HD IL-2 followed strategically by continuous TMZ.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930514.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


17. Powell SF, Dudek AZ: Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma.
  • : e20007 Background: HD IL-2 has been shown to produce durable responses in patients with metastatic melanoma.
  • METHODS: A retrospective analysis was performed all adult patients with Stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at our institution.
  • HD IL-2 was given I.V. every eight hours as a bolus over 15 minutes at a dose of 600,000 IU/kg.
  • RESULTS: A total of 15 patients with metastatic melanoma had been treated with HD IL-2 at our institution.
  • Complete response (CR) was seen in 6.67% (N=1), partial response (PR) in 6.67% (N=1), mixed response (MR) in 6.67% (N=1), and stable disease (SD) in 13.33% (N=2).
  • Average time to disease progression (TTDP) was 5.67 months in those with a PR or SD.
  • Two patients with brain metastases had subsequently complete resolution of the brain lesions after HD IL-2 therapy.
  • One of these patients has a CR and is disease free 34 months out from therapy.
  • The other had PR and is currently alive with disease, but has no recurrence of the brain lesion after over 19 months.
  • On average patients tolerated 10.5 HD IL-2 doses with the first course and 8.8 doses with the second course.
  • HD IL-2 has typically been avoided in patients with brain metastases due to concern for neurologic complications from the capillary leak syndrome caused by treatment.
  • We propose further evaluation of this ineligibility for HD IL-2, since carefully selected patients with brain metastases may derive benefit from this treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Klepin HD, Song EY, Geiger AM, Tooze JA, Foley KL: Influence of age on receipt of chemotherapy for adult Medicaid beneficiaries with metastatic colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of age on receipt of chemotherapy for adult Medicaid beneficiaries with metastatic colorectal cancer.
  • : 9548 Background: Although advances in systemic treatment for metastatic colorectal cancer (CRC) have improved survival, it is unclear if this treatment is administered routinely among vulnerable individuals.
  • Our objective was to describe treatment patterns for low income individuals with metastatic CRC and evaluate the influence of age on delivery of treatment in the context of patient, community, and health care setting characteristics.
  • METHODS: Matched North Carolina Cancer Registry and Medicaid claims data were used to identify a cohort of 390 patients with metastatic CRC diagnosed between 1999 and 2002.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963615.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yeh SM, Hwang SJ, Chen HC: Treatment of severe metastatic calcification in hemodialysis patients. Hemodial Int; 2009 Apr;13(2):163-7
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of severe metastatic calcification in hemodialysis patients.
  • We report a uremic patient who developed uncontrolled hyperparathyroidism rapidly within 6 months after commencing hemodialysis (HD) therapy, with clinical presentations of tumoral calcinosis, calciphylaxis, and myocardial calcifications.
  • This case highlights an unusual and rapid development of tertiary hyperparathyroidism, the importance of tight calcium/phosphate control in uremic patients, the potential hazards of a high calcium concentration dialysate, and the dangers of the overzealous use of active vitamin D therapy in HD patients with uncontrolled hyperparathyroidism.
  • [MeSH-minor] Adult. Combined Modality Therapy. Education, Medical, Graduate. Fatal Outcome. Female. Humans. Nephrology / education. Parathyroidectomy. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432688.001).
  • [ISSN] 1492-7535
  • [Journal-full-title] Hemodialysis international. International Symposium on Home Hemodialysis
  • [ISO-abbreviation] Hemodial Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Hemodialysis Solutions
  •  go-up   go-down


20. Comella P, Massidda B, Filippelli G, Palmeri S, Natale D, Farris A, De Vita F, Buzzi F, Tafuto S, Maiorino L, Mancarella S, Leo S, Lorusso V, De Lucia L, Roselli M: Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol; 2005 Jun;16(6):878-86
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.
  • PATIENTS AND METHODS: Patients with measurable metastatic colorectal carcinoma were randomly allocated to receive: IRI 200 mg/m(2) on day 1, l-FA 250 mg/m(2) intravenously plus 5-FU 850 mg/m(2) on day 2 (IRIFAFU); or OXA 100 mg/m(2) on day 1, l-FA 250 mg/m(2) plus 5-FU 1050 mg/m(2) on day 2 [OXAFAFU high dose (hd)].

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2005 Jun;16(6):845-6 [15890668.001]
  • (PMID = 15837702.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB: Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol; 2006 Feb;30(2):141-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.
  • Most (up to 71%) of renal cell neoplasms occurring in patients with end-stage renal disease (ESRD), particularly with acquired cystic disease of the kidney (ACDK), have been reported to be papillary renal cell carcinoma (RCC).
  • The more common tumor that we have designated as "acquired cystic disease-associated RCC" was seen as the dominant mass in 24 (36%) of 66 of the kidneys, and it formed the most common tumor type among the smaller nondominant masses, as well.
  • The other category was "clear-cell papillary RCC of the end-stage kidneys," present as the dominant mass in 15 (23%) of the 66 kidneys and occurring in both the ACDK and noncystic ESRD.
  • Only the acquired cystic disease-associated RCC showed lymph node metastases in 2 cases and sarcomatoid features in 2 more cases.
  • One of the latter 2 died with widespread metastatic disease within 34 months of nephrectomy.
  • Acquired cystic disease-associated RCC is the commonest tumor subtype in ESRD, and biologically it appears to be more aggressive than the other tumor subtypes in ESRD.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434887.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Katzberg HD, Miller RG, Katz J: Thymic carcinoma in myasthenia gravis developing years after thymectomy. Muscle Nerve; 2009 Jul;40(1):137-8
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The late appearance of metastatic thymoma raises questions about monitoring for these patients.
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Myasthenia gravis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19533649.001).
  • [ISSN] 0148-639X
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Zini A, Czerninski R, Sgan-Cohen HD: Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J Oral Pathol Med; 2010 Apr;39(4):299-305
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoma and sarcoma were the most prevalent under the age of 20.
  • Melanomas and metastatic disease revealed the lowest survival rate, while invasive or infiltrating basal cell carcinoma in the lips had the highest rate.
  • [MeSH-minor] Adult. Age Factors. Aged. Arabs / statistics & numerical data. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / mortality. Carcinoma, Squamous Cell / epidemiology. Epidemiologic Studies. Female. Gingival Neoplasms / epidemiology. Humans. Incidence. Israel / epidemiology. Jews / statistics & numerical data. Lip Neoplasms / epidemiology. Lymphoma / epidemiology. Male. Melanoma / epidemiology. Melanoma / mortality. Middle Aged. Mouth Floor / pathology. Palatal Neoplasms / epidemiology. Prevalence. Sarcoma / epidemiology. Sex Factors. Survival Rate. Tongue Neoplasms / epidemiology. Young Adult

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040019.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


24. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG Jr: Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis; 2007 Jan 15;44(2):190-6
Hazardous Substances Data Bank. CEFAZOLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients receiving vancomycin (n=77) tended to be younger (51 vs. 57 years; P=.06) and had a lower rates of metastatic complications at presentation (11.7% vs. 36.7%; P=.001) than did those receiving cefazolin (n=46).
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Microbial Sensitivity Tests. Middle Aged. Odds Ratio. Renal Dialysis. Risk Factors. Staphylococcus aureus / drug effects. Treatment Failure

  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2015 Apr 15;60(8):1290-1 [25609683.001]
  • [CommentIn] Clin Infect Dis. 2015 Apr 15;60(8):1291-2 [25609681.001]
  • (PMID = 17173215.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 059111; United States / NICHD NIH HHS / HD / HD-044799-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 6Q205EH1VU / Vancomycin; IHS69L0Y4T / Cefazolin
  •  go-up   go-down


25. Tung WC, Huang YJ, Leung SW, Kuo FY, Tung HD, Wang JH, Hung CH, Lee CM, Changchien CS, Yeh SA, Sun LM, Huang EY, Hsu HC, Wang CJ, Lu SN: Incidence of needle tract seeding and responses of soft tissue metastasis by hepatocellular carcinoma postradiotherapy. Liver Int; 2007 Mar;27(2):192-200
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic lesions could be divided into procedure related (PR), which were located at the liver span and were related to invasive procedures, and non-procedure related (NPR), which were in extrahepatic areas.
  • [MeSH-minor] Administration, Cutaneous. Adult. Aged. Biopsy, Fine-Needle / adverse effects. Ethanol / administration & dosage. Ethanol / therapeutic use. Female. Humans. Iatrogenic Disease. Incidence. Injections / adverse effects. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311613.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


26. Xue HD, Li S, Sun F, Sun HY, Jin ZY, Yang JX, Yu M: Clinical application of body diffusion weighted MR imaging in the diagnosis and preoperative N staging of cervical cancer. Chin Med Sci J; 2008 Sep;23(3):133-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ADC value of normal or inflammatory lymph nodes was also compared with that of metastatic ones.
  • In patients had lymphadenectomy (n = 24), totally 67 lymph nodes including 16 metastatic lymph nodes were pathologically analyzed, and DWI showed 66 (98.5%) out of them.
  • ADC values of normal/inflammatory and metastatic lymph nodes were (1.07 +/- 0.16) x 10(-3) and (0.77 +/- 0.13) x 10(-3) mm2/s (P < 0.01).
  • Receiver operating characteristic (ROC) curve of ADC value of metastatic lymph node showed that area under curve was 0.961.


27. Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S: Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol; 2010 Dec;21(12):2342-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: FINDER1 compared efficacy, tolerability and pharmacokinetics (PK) of three fulvestrant dose regimens in postmenopausal Japanese women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer recurring or progressing after prior endocrine therapy.
  • Postmenopausal women with ER-positive advanced breast cancer were randomised to 28-day cycles of fulvestrant approved dose (AD), loading dose (LD) or high dose (HD) until disease progression.
  • RESULTS: Hundred and forty-three patients (median age 61 years) received fulvestrant AD (n = 45), LD (n = 51) or HD (n = 47).
  • ORR was similar across dose regimens: 11.1%, 17.6% and 10.6% for AD, LD and HD, respectively, with overlapping confidence intervals.
  • TTP and CBR were also similar between groups (median TTP: 6.0, 7.5 and 6.0 months, respectively; CBR: 42.2%, 54.9% and 46.8% for AD, LD and HD, respectively).
  • C(max) and area under the plasma concentration-time curve were dose proportional and PK steady state was reached earlier with LD and HD than with AD.
  • CONCLUSION: Fulvestrant AD, LD and HD had similar efficacy and tolerability profiles in postmenopausal Japanese women with ER-positive advanced breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20494961.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol
  •  go-up   go-down


28. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F: The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer; 2010 Nov;46(16):2926-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the following expansion phase, patients with metastatic renal cell carcinoma (RCC) (n=12) were treated at the RD of L19-IL2.
  • We observed stable disease in 17/33 patients (51%) and 15/18 with mRCC (83%) after two cycles.
  • [MeSH-minor] Adult. Aged. Animals. Antibodies, Neoplasm / blood. Area Under Curve. Female. Humans. Infusions, Intravenous. Macaca fascicularis. Male. Middle Aged. Oncogene Proteins, Fusion / immunology. Rats. Rats, Sprague-Dawley. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20797845.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01058538
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / L19-IL2 immunocytokine; 0 / Oncogene Proteins, Fusion; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


29. Worden FP, Taylor JM, Biermann JS, Sondak VK, Leu KM, Chugh R, McGinn CJ, Zalupski MM, Baker LH: Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol; 2005 Jan 1;23(1):105-12
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to compare the efficacy and toxicity of doxorubicin with high-dose (HD) ifosfamide or standard-dose (SD) ifosfamide in patients with STS.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with STS were randomly assigned to receive doxorubicin 60 mg/m(2) and either SD ifosfamide (1.5 g/m(2)/d, days 1 through 4) or HD ifosfamide (3.0 g/m(2), days 1 through 4) every 21 days.
  • Patients were stratified by the presence or absence of metastatic disease.
  • End points were overall survival (OS), 1-year disease-free survival (DFS), and toxicity.
  • RESULTS: The study group consisted of 79 patients (52 patients with localized disease and 27 patients with metastases).
  • There was no significant difference in 1-year DFS comparing SD ifosfamide with HD ifosfamide (55% v 52%; P = .81).
  • For SD ifosfamide, 2- and 3-year OS were 73% and 52% versus 57% and 49% for HD ifosfamide (P = .34).
  • The incidence of grade 3/4 neutropenia, anemia, and thrombocytopenia were 49%, 23%, and 10%, respectively, on the SD ifosfamide arm, compared with 88%, 58%, and 63%, respectively, on the HD ifosfamide arm.
  • There were five early deaths, all on the HD ifosfamide arm.
  • CONCLUSION: When combined with doxorubicin, HD ifosfamide did not improve 1-year DFS and OS.
  • Toxicity was clearly greater with the HD ifosfamide arm, and lack of outcome differences might be explained by toxicities with HD ifosfamide.
  • These results suggest that HD ifosfamide combination regimens should not be used as first-line therapy for patients with STS.
  • [MeSH-minor] Adolescent. Adult. Aged. Anemia / chemically induced. Child. Drug Tolerance. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neutropenia / chemically induced. Prognosis. Survival Rate. Thrombocytopenia / chemically induced

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2014 Jan 1;32(1):63. Dosage error in article text
  • [ErratumIn] J Clin Oncol. 2006 Sep 1;24(25):4223
  • (PMID = 15625365.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


30. Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, Fox S, Graham H, Lüchtenborg M, Sinnett HD, Cross NC, Coombes RC: Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer; 2005 Mar 10;114(1):94-100
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Together, both have shown promise for monitoring therapeutic efficacy in patients with metastatic breast cancer.
  • The aim of this study was to determine the feasibility and value of these assays for minimal residual disease (MRD) in monitoring efficacy of adjuvant therapy following surgery for primary breast cancer.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Feasibility Studies. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm, Residual / diagnosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15523696.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 68238-35-7 / Keratins
  •  go-up   go-down


31. Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JA, Jeys LM, Franchi A, Scoccianti G, Campanacci D, Capanna R, Aparicio J, Tabone MD, Holzer G, Abdolvahab F, Funovics P, Dominkus M, Ilhan I, Berrak SG, Patino-Garcia A, Sierrasesumaga L, San-Julian M, Garraus M, Petrilli AS, Filho RJ, Macedo CR, Alves MT, Seiwerth S, Nagarajan R, Cripe TP, Ioannidis JP: Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer; 2009 Sep;45(13):2367-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In multivariate models the mortality risk increased with older age, presence of metastatic disease at diagnosis, development of local recurrence when the patient was first seen, use of amputation instead of limb salvage/wide resection, employment of unusual treatments, use of chemotherapeutic regimens other than anthracycline and platinum and use of methotrexate.
  • The risk of metastasis increased when metastatic disease was present at the time the patient was first seen and also increased with use of amputation or unusual treatment combinations or chemotherapy regimens not including anthracycline and platinum.
  • [MeSH-minor] Adolescent. Confidence Intervals. Female. Humans. Male. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349163.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C, German Testicular Cancer Study Group: Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol; 2007 Dec 20;25(36):5742-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the feasibility and the toxicity of sequential, dose-intensified chemotherapy combined with paclitaxel plus peripheral blood-derived hematopoietic stem-cell support (PBSC) for patients with untreated metastatic germ cell tumors (GCTs) who have poor International Germ Cell Consensus Cancer Group prognostic features.
  • PATIENTS AND METHODS: Paclitaxel was added to high-dose (HD) etoposide, ifosfamide, and cisplatin (VIP; etoposide 1,500 mg/m2, ifosfamide 10,000 mg/m2, and cisplatin 100 mg/m2; cumulative dose; days -6 through -2 per cycle) at three dose levels (135, 175, and 225 mg/m2) applied on day -6.
  • One cycle of standard VIP was administered before start of HD-VIP plus paclitaxel cycles to collect autologous PBSC.
  • CONCLUSION: Dose-intensive, sequential HD-VIP plus paclitaxel up to a dose of 225 mg/m2 in patients with poor prognosis GCT is a feasible approach.
  • [MeSH-minor] Adolescent. Adult. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Feasibility Studies. Hematopoietic Stem Cell Transplantation. Humans. Ifosfamide / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoadjuvant Therapy. Paclitaxel / administration & dosage. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089869.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


33. Li S, Xue HD, Li J, Sun F, Jiang B, Liu D, Sun HY, Jin ZY: Application of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lymphoma. Chin Med Sci J; 2008 Sep;23(3):138-44
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lymphoma.
  • OBJECTIVE: To evaluate the clinical impact of whole body diffusion weighted imaging (WB-DWI) on diagnosis and staging of malignant lymphoma.
  • RESULTS: WB-DWI was positive in all 18 cases with lymphoma, 5 cases with metastatic lymph nodes and 4 of 8 cases with benign lymphadenopathy.
  • The mean ADC value of lymphomatous, metastatic and benign lymph nodes was (0.87 +/- 0.17) x 10(-3), (0.98 +/- 0.09) x 10(-3) and (1.20 +/- 0.10) x 10(-3) mm2/s.
  • The sensitivity, specificity and accuracy of WB-DWI in diagnosis of lymphoma were 100% (18/18), 30.8% (4/13) and 71.0% (22/31).
  • Sixteen of eighteen cases (88.9%) of lymphoma were accurately staged in accordance with clinical staging.
  • CONCLUSIONS: WB-DWI is a sensitive, but less specific technique for diagnosis of lymphoma.
  • It is difficult to differentiate lymphomatous from metastatic lymph nodes using WB-DWI.
  • However, it is a valuable imaging modality for staging of patients with malignant lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853847.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Li S, Sun F, Jin ZY, Xue HD, Li ML: Whole-body diffusion-weighted imaging: technical improvement and preliminary results. J Magn Reson Imaging; 2007 Oct;26(4):1139-44
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 30 patients with histologically-proven malignant disease were scanned under the final protocol using a built-in body coil.
  • WB-DWI might have important clinical value for the detection of primary and metastatic malignancies within the whole body.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Diffusion. Female. Humans. Imaging, Three-Dimensional. Lung Neoplasms / pathology. Lymphoma / diagnosis. Male. Middle Aged. Neoplasm Metastasis. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17896396.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R, European EGFR Workshop Group: Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol; 2010 Oct;5(10):1706-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The EGFR-TKI gefitinib has been approved in Europe for the treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of the EGFR TK.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871269.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Investigator] Arns-Dietl M; Berger W; Filipits M; Hack M; Hegedús B; Hilbe W; Hochmair M; Hoda MA; Huemer F; Hulla W; Kirchbacher K; Koller H; Kreuzer S; Pedram E; Pirker R; Popper H; Prüfert-Holzinger P; Reiter M; Wasicky R; Zielinski C; Zöchbauer-Mller S; Badri N; Gutendorf B; Hansen C; Koelsch C; Kölsch C; Lebrun A; Praet M; Tchakov I; Teugels E; Van De Walle E; Vandenberghe P; Ledecky J; Petruzelka L; Ryska A; Zatloukal P; de Stricker K; Grauslund M; Guldhammer-Skov B; Hager H; Dauplat MM; Grunenwald D; Järvi J; Knuttila A; Salmenkivi K; Chen Y; Cui T; De Bals B; Dietel M; Eberhardt W; Eder I; Hein B; Herth F; Hongyu L; Huber RM; Kruetzfeldt K; Manegold C; Penzel R; Schirmacher P; Thomas M; Yang L; Gately K; Boukovinas I; Moulis A; Murray S; Saetta A; Vassias A; Bazzola L; Buttitta F; Dono M; Gambacorta M; Marchetti A; Mari E; Normanno N; Rossi A; Troncone G; Veronese S; Zupo S; Almeida M; Amara T; Carvalho L; Lima AR; Benlloch S; Foncillas JG; Arenas CG; Garcia ML; Lopez-Rios F; Sanz J; Taron M; Miquel SZ; Botling J; Brattström D; Ekman S; Elmberger G; Johansson L; Koyi H; Spinnars J; Sundqvist K; Frattini M; Jehle S; Stahel R; Dingemans AM; Marang M; Nederlof P; Smit E; Thunnissen E; Akpir Soydan HD; Aydiner A; Yilmazbayhen ED; Butler R; Clark C; Cook I; Cree I; De Castro DG; Horsfield A; Kerr K; McWalter G; Taniere P; Theaker J; Walker G; Gandara D; Hirsch F
  •  go-up   go-down


36. DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE, Suit HD: Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):492-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 41 patients, 27 (65.85%) were treated for localized disease at primary presentation, 10 (24.4%) for local recurrence, and 4 (9.8%) for metastatic disease.
  • Patients with either gross or subtotal resection had a greater rate of local control, survival, and disease-free survival compared with those who underwent biopsy only at 5 years (77.7% +/- 7.5% vs. 40% +/- 21% [p <0.001], 73.9% +/- 8.1% vs. 25% +/- 21.6% [p <0.001], and 51.9% +/- 9.1% vs. 25% +/- 21.6% [p <0.01], respectively).
  • It appears to be more effective in situations in which microscopic or minimal residual disease is being treated.
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Dose-Response Relationship, Radiation. Humans. Middle Aged. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667972.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA21239-23
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


37. Shin HD, Park BL, Cheong HS, Yoon JH, Kim YJ, Lee HS: SPP1 polymorphisms associated with HBV clearance and HCC occurrence. Int J Epidemiol; 2007 Oct;36(5):1001-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SPP1 is overexpressed in metastatic hepatocellular carcinoma (HCC), and therefore could act as both a diagnostic marker and a potential therapeutic target for metastatic HCC.
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Chromosome Mapping. Disease Progression. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Haplotypes. Hepatitis B virus / isolation & purification. Humans. Logistic Models. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496055.001).
  • [ISSN] 0300-5771
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / SPP1 protein, human; 106441-73-0 / Osteopontin
  •  go-up   go-down


38. Schleinitz MD, DePalo D, Blume J, Stein M: Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med; 2006 Dec;21(12):1253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We incorporated each subject's utilities into a Markov model to determine whether her quality-adjusted life expectancy would be maximized with chemotherapy for a hypothetical, current diagnosis of stage II breast cancer.
  • RESULTS: Median utilities for the 8 health states were: stage I disease, 0.91 (interquartile range 0.50 to 1.00); stage II, 0.75 (0.26 to 0.99); stage III, 0.51 (0.25 to 0.94); stage IV (estrogen receptor positive), 0.36 (0 to 0.75); stage IV (estrogen receptor negative), 0.40 (0 to 0.79); chemotherapy 0.50 (0 to 0.92); hormonal therapy 0.58 (0 to 1); and radiation therapy 0.83 (0.10 to 1).
  • Utilities for early stage disease and treatment modalities, but not metastatic disease, varied with socio-demographic characteristics.
  • One hundred and twenty-two of 156 subjects had utilities that maximized quality-adjusted life expectancy given stage II breast cancer with chemotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] WMJ. 1999 Dec;98(8):37-9 [10639893.001]
  • [Cites] J Gen Intern Med. 2005 Jan;20(1):38-44 [15693926.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1455-61 [11230491.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1577-85 [11401308.001]
  • [Cites] Natl Vital Stat Rep. 2001 Sep 21;49(8):1-113 [11591077.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):471-3 [11929941.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1759-66 [12365025.001]
  • [Cites] South Med J. 2002 Oct;95(10):1145-8 [12425498.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):134-47 [12491515.001]
  • [Cites] Cancer Metastasis Rev. 2003 Mar;22(1):55-65 [12716037.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(1):21-31 [14531494.001]
  • [Cites] BMC Med Inform Decis Mak. 2001;1:2 [11545684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):34-42 [14697418.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):184-94 [15009798.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):301-7 [15951457.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Decis Making. 2000 Jan-Mar;20(1):72-8 [10638539.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Ann Intern Med. 2003 Jan 21;138(2):90-7 [12529090.001]
  • [Cites] J Eval Clin Pract. 2003 Feb;9(1):69-82 [12558704.001]
  • [Cites] Med Decis Making. 2003 Mar-Apr;23(2):167-76 [12693879.001]
  • [Cites] Prev Med. 2004 Jul;39(1):1-10 [15207980.001]
  • [Cites] CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55 [15224974.001]
  • [Cites] Clin Prostate Cancer. 2004 Jun;3(1):31-7 [15279688.001]
  • [Cites] Health Serv Res. 1972 Summer;7(2):118-33 [5044699.001]
  • [Cites] Med Decis Making. 1982 Winter;2(4):449-62 [7182703.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] Med Care. 1989 Mar;27(3 Suppl):S190-204 [2522159.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):326-31 [8321261.001]
  • [Cites] Med Decis Making. 1993 Jul-Sep;13(3):212-7 [8412549.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1395-402 [8839544.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(3):261-73 [8877006.001]
  • [Cites] Breast Cancer Res Treat. 1996;40(1):65-74 [8888153.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):327-37 [8909641.001]
  • [Cites] Med Decis Making. 1997 Jan-Mar;17(1):21-32 [8994148.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):136-41 [9107608.001]
  • [Cites] Oncol Nurs Forum. 1998 Apr;25(3):555-62 [9568610.001]
  • [Cites] Oncol Nurs Forum. 1998 Jun;25(5):887-95 [9644705.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1409-15 [10451447.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1047-53 [10526998.001]
  • [Cites] Med Care. 2005 Feb;43(2):141-8 [15655427.001]
  • [Cites] Med Care. 2000 Sep;38(9 Suppl):II160-4 [10982102.001]
  • (PMID = 16961753.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NICHD NIH HHS / HD / HD43447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC1924747
  •  go-up   go-down


39. Mrus JM, Braun L, Yi MS, Linde-Zwirble WT, Johnston JA: Impact of HIV/AIDS on care and outcomes of severe sepsis. Crit Care; 2005;9(6):R623-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When compared with those with severe sepsis and HIV/AIDS, patients with severe sepsis without HIV/AIDS were universally more likely to be admitted to the intensive care unit, even when they had comorbid illnesses with equal or worse expected in-hospital mortality (e.g., metastatic cancer).

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Critical Care.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2004 May;125(5):1800-4 [15136393.001]
  • [Cites] J Pediatr. 2004 May;144(5):595-601 [15126992.001]
  • [Cites] Am Rev Respir Dis. 1986 Nov;134(5):891-6 [3777686.001]
  • [Cites] Ann Intern Med. 1989 Sep 15;111(6):525-32 [2549825.001]
  • [Cites] Int J Technol Assess Health Care. 1990;6(2):272-81 [2203703.001]
  • [Cites] J Acquir Immune Defic Syndr. 1991;4(10):1015-24 [1832459.001]
  • [Cites] Crit Care Med. 1992 May;20(5):683-90 [1572195.001]
  • [Cites] J Health Adm Educ. 1992 Winter;10(1):113-28 [10118033.001]
  • [Cites] Chest. 1992 Jun;101(6):1481-3 [1600757.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] AIDS Care. 1993;5(1):105-16 [7681693.001]
  • [Cites] Am J Public Health. 1993 Oct;83(10):1433-7 [8214234.001]
  • [Cites] JAMA. 1995 Jan 18;273(3):230-5 [7807663.001]
  • [Cites] Chest. 1995 Feb;107(2):506-10 [7842785.001]
  • [Cites] Crit Care Med. 1995 Jun;23(6):1040-7 [7774214.001]
  • [Cites] Am J Hosp Palliat Care. 1995 Nov-Dec;12(6):14, 17-27 [7495635.001]
  • [Cites] Ann Epidemiol. 1995 Sep;5(5):337-46 [8653205.001]
  • [Cites] Pharmacoeconomics. 1996 Jul;10(1):72-8 [10160471.001]
  • [Cites] AIDS Patient Care STDS. 1996 Jun;10(3):168-70 [11361617.001]
  • [Cites] Prim Care. 1997 Sep;24(3):607-15 [9271695.001]
  • [Cites] Intensive Care Med. 1997 Oct;23(10):1018-23 [9407236.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):253-61 [9495226.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1497-503 [9809730.001]
  • [Cites] An Med Interna. 1999 Jan;16(1):8-14 [10089644.001]
  • [Cites] Pharmacoeconomics. 1999 Sep;16(3):307-15 [10558042.001]
  • [Cites] J Palliat Care. 1995 Summer;11(2):48-9 [7541077.001]
  • [Cites] AIDS. 2004 Jul 2;18(10):1429-33 [15199319.001]
  • [Cites] Arch Intern Med. 2000 Feb 28;160(4):541-7 [10695695.001]
  • [Cites] Eff Clin Pract. 2000 Jan-Feb;3(1):25-30 [10788033.001]
  • [Cites] Lancet. 2000 Apr 1;355(9210):1158-9 [10791383.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):393-8 [10934059.001]
  • [Cites] Crit Care Med. 2001 Mar;29(3):548-56 [11373418.001]
  • [Cites] Ann Intern Med. 2001 Jul 3;135(1):17-26 [11434728.001]
  • [Cites] Crit Care Med. 2001 Jul;29(7):1303-10 [11445675.001]
  • [Cites] Crit Care Med. 2001 Jul;29(7 Suppl):S109-16 [11445744.001]
  • [Cites] HIV Clin. 2001 Fall;13(4):12-5 [11810788.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Aug 1;166(3):262-7 [12153955.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Mar 1;167(5):695-701 [12433670.001]
  • [Cites] Psychiatr Serv. 2003 Sep;54(9):1240-6 [12954940.001]
  • [Cites] Lancet. 2003 Sep 13;362(9387):877-8 [13678976.001]
  • [Cites] Chest. 2004 Feb;125(2):548-56 [14769737.001]
  • [CommentIn] Crit Care. 2005;9(6):629-30 [16356250.001]
  • (PMID = 16280060.001).
  • [ISSN] 1466-609X
  • [Journal-full-title] Critical care (London, England)
  • [ISO-abbreviation] Crit Care
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K23 HD046690; United States / NICHD NIH HHS / HD / K23 HD044556-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1378113
  •  go-up   go-down


40. Bartsch R, Fromm S, Rudas M, Wenzel C, Harbauer S, Roessler K, Kitz K, Steger GG, Weitmann HD, Poetter R, Zielinski CC, Dieckmann K: Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. Radiother Oncol; 2006 Sep;80(3):313-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a multivariate analysis (Cox regression) to explore which factors are able to influence significantly cerebral time to progression (TTP) and overall survival (metastatic sites [visceral versus non-visceral], Karnofsky performance score [KPS], age, intensified local treatment [boost irradiation, neuro-surgical resection] further systemic treatment).
  • Factors significantly influencing survival were intensified local treatment (p = 0.004), metastatic sites (p = 0.008), KPS (p = 0.006), and palliative systemic treatment (p < 0.001).
  • CONCLUSION: As shown by the significant influence of metastatic sites, some patients die from their advanced systemic tumour situation before they would die from cerebral progression.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Humans. Karnofsky Performance Status. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymphatic Metastasis. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiother Oncol. 2007 Mar;82(3):356-7; author reply 357 [17126939.001]
  • (PMID = 16959347.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


41. Iwakawa R, Kohno T, Anami Y, Noguchi M, Suzuki K, Matsuno Y, Mishima K, Nishikawa R, Tashiro F, Yokota J: Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma. Clin Cancer Res; 2008 Jun 15;14(12):3746-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, homozygous deletions (HD) have been frequently detected in cell lines; however, their frequency and specificity is not well-established in primary tumors.
  • EXPERIMENTAL DESIGN: Multiple ligation-dependent probe amplification was used for the detection of p16 HDs in 28 primary small-sized lung adenocarcinomas and 22 metastatic lung adenocarcinomas to the brain.
  • No significant associations were observed between p16 HDs and gender, age, smoking history, stage, and prognosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Frequency. Genetic Linkage. Homozygote. Humans. Male. Middle Aged. Models, Biological. Mutation. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559592.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Stineman MG, Kurichi JE, Kwong PL, Maislin G, Reker DM, Vogel WB, Prvu-Bettger JA, Bidelspach DE, Bates BE: Survival analysis in amputees based on physical independence grade achievement. Arch Surg; 2009 Jun;144(6):543-51; discussion 552
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas metastatic cancer and hemodialysis remained significantly associated with reduced survival (both P < or = .001), anatomical amputation level was not significant when rehabilitation discharge grade and other diagnostic conditions were considered.

  • MedlinePlus Health Information. consumer health - Limb Loss.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vasc Surg. 2003 Jul;38(1):7-14 [12844082.001]
  • [Cites] Arch Phys Med Rehabil. 2003 Jun;84(6):803-11 [12808530.001]
  • [Cites] Arch Phys Med Rehabil. 2003 Jan;84(1):29-37 [12589617.001]
  • [Cites] Med Care. 2003 Jan;41(1):70-83 [12544545.001]
  • [Cites] J Rehabil Res Dev. 2001 May-Jun;38(3):341-5 [11440266.001]
  • [Cites] Surgery. 2001 Jul;130(1):21-9 [11436008.001]
  • [Cites] Arch Phys Med Rehabil. 2000 Nov;81(11):1468-78 [11083350.001]
  • [Cites] Br J Surg. 2000 Mar;87(3):328-37 [10718803.001]
  • [Cites] J Rehabil Res Dev. 1999 Jan;36(1):55-9 [10659895.001]
  • [Cites] Age Ageing. 2003 Nov;32(6):619-25 [14600003.001]
  • [Cites] Behav Res Methods. 2008 Aug;40(3):879-91 [18697684.001]
  • [Cites] Arch Phys Med Rehabil. 2007 Oct;88(10):1249-55 [17908565.001]
  • [Cites] Am J Surg. 2003 Nov;186(5):449-54 [14599605.001]
  • [Cites] Arch Phys Med Rehabil. 2003 Nov;84(11):1647-56 [14639565.001]
  • [Cites] J Am Soc Nephrol. 2004 Feb;15(2):427-34 [14747390.001]
  • [Cites] J Bone Joint Surg Am. 2004 Aug;86-A(8):1636-45 [15292410.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Prosthet Orthot Int. 1989 Aug;13(2):63-9 [2780262.001]
  • [Cites] Am J Med. 1992 Dec;93(6):663-9 [1466363.001]
  • [Cites] Arch Phys Med Rehabil. 1994 Feb;75(2):127-32 [8311667.001]
  • [Cites] Scand J Rehabil Med. 1994 Sep;26(3):115-9 [7801060.001]
  • [Cites] Med Care. 1995 Sep;33(9):906-21 [7666705.001]
  • [Cites] J Clin Epidemiol. 1996 Feb;49(2):193-201 [8606320.001]
  • [Cites] Am J Phys Med Rehabil. 1996 Jan-Feb;75(1):9-14 [8645444.001]
  • [Cites] Prosthet Orthot Int. 1996 Aug;20(2):79-87 [8876000.001]
  • [Cites] Arch Phys Med Rehabil. 1996 Nov;77(11):1101-8 [8931518.001]
  • [Cites] Arch Phys Med Rehabil. 1997 Jun;78(6):636-43 [9196472.001]
  • [Cites] JAMA. 1998 Apr 15;279(15):1187-93 [9555758.001]
  • [Cites] Prosthet Orthot Int. 1998 Apr;22(1):10-16 [9604271.001]
  • [Cites] Disabil Rehabil. 1998 Oct;20(10):380-4 [9793752.001]
  • [Cites] JAMA. 1963 Sep 21;185:914-9 [14044222.001]
  • [Cites] Med Care. 2005 Dec;43(12):1194-202 [16299430.001]
  • [Cites] Am J Surg. 2006 Apr;191(4):443-7 [16531133.001]
  • [Cites] J Am Geriatr Soc. 2006 Apr;54(4):667-73 [16686880.001]
  • [Cites] J Rehabil Res Dev. 2006 Nov-Dec;43(7):917-28 [17436177.001]
  • [Cites] J Am Geriatr Soc. 2007 Jun;55(6):900-6 [17537091.001]
  • [Cites] Gerontology. 2007;53(5):255-9 [17435390.001]
  • (PMID = 19528388.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD042588; United States / NICHD NIH HHS / HD / R01 HD042588-05A2; United States / NICHD NIH HHS / HD / R56 HD042588; United States / NICHD NIH HHS / HD / R01-HD042588
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS162284; NLM/ PMC2869628
  •  go-up   go-down






Advertisement